In lung adenocarcinoma, the mutational spectrum is dominated by EGFR and KRAS mutations. Improved knowledge about genomic and transcriptional alterations in and between mutation-defined subgroups may identify genes involved in disease development or progression
The adenocarcinoma of the lung has recently shown peculiar molecular characteristics, which relate w...
The adenocarcinoma of the lung has recently shown peculiar molecular characteristics, which relate w...
Lung adenocarcinoma (LAD) has extreme genetic variation among patients, which is currently not well ...
Introduction: In lung adenocarcinoma, the mutational spectrum is dominated by EGFR and KRAS mutation...
<div><p>Introduction</p><p>In lung adenocarcinoma, the mutational spectrum is dominated by <i>EGFR</...
In lung adenocarcinoma, EGFR and KRAS mutations dominate the mutational spectrum and have clear ther...
IntroductionWe investigated EGFR and KRAS alterations among atypical adenomatous hyperplasia and sma...
Recent studies have reported that clinical response to epidermal growth factor receptor (EGFR) inhib...
IntroductionThe discovery that somatic mutations in the epidermal growth factor receptor (EGFR) gene...
Increasing understanding of genomic changes in cancer is transforming the diagnosis and treatment of...
BackgroundSomatic mutations in EGFR (exons 19 and 21) and KRAS (exon 2) are found in lung adenocarci...
Activated epidermal growth factor receptor (EGFR) and Kirsten rat sarcoma viral oncogene homolog (KR...
Objectives: This study aims to determine the association of EGFR/KRAS mutation status with histologi...
Background: Lung cancer is the leading cause of cancer-related death and one of the most common canc...
Tumor recurrence is frequent and survival rates remain extremely low in lung adenocarcinoma (ADC). W...
The adenocarcinoma of the lung has recently shown peculiar molecular characteristics, which relate w...
The adenocarcinoma of the lung has recently shown peculiar molecular characteristics, which relate w...
Lung adenocarcinoma (LAD) has extreme genetic variation among patients, which is currently not well ...
Introduction: In lung adenocarcinoma, the mutational spectrum is dominated by EGFR and KRAS mutation...
<div><p>Introduction</p><p>In lung adenocarcinoma, the mutational spectrum is dominated by <i>EGFR</...
In lung adenocarcinoma, EGFR and KRAS mutations dominate the mutational spectrum and have clear ther...
IntroductionWe investigated EGFR and KRAS alterations among atypical adenomatous hyperplasia and sma...
Recent studies have reported that clinical response to epidermal growth factor receptor (EGFR) inhib...
IntroductionThe discovery that somatic mutations in the epidermal growth factor receptor (EGFR) gene...
Increasing understanding of genomic changes in cancer is transforming the diagnosis and treatment of...
BackgroundSomatic mutations in EGFR (exons 19 and 21) and KRAS (exon 2) are found in lung adenocarci...
Activated epidermal growth factor receptor (EGFR) and Kirsten rat sarcoma viral oncogene homolog (KR...
Objectives: This study aims to determine the association of EGFR/KRAS mutation status with histologi...
Background: Lung cancer is the leading cause of cancer-related death and one of the most common canc...
Tumor recurrence is frequent and survival rates remain extremely low in lung adenocarcinoma (ADC). W...
The adenocarcinoma of the lung has recently shown peculiar molecular characteristics, which relate w...
The adenocarcinoma of the lung has recently shown peculiar molecular characteristics, which relate w...
Lung adenocarcinoma (LAD) has extreme genetic variation among patients, which is currently not well ...